CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
donor lymphocytesbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00534118
NCT00534118N/ACompleted
CompareCT.gov

Cellular Infusions in Patients With Recurrent or Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplant

Roswell Park Cancer Institute·interventional·Posted Sep 24, 2007·Updated Aug 26, 2020

In Brief

A clinical study evaluating donor lymphocytes for Leukemia and 3 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant. PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating patients with recurrent or persistent hematologic cancer after donor stem cell transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 24, 2007
Enrollment StartOct 1, 2003
Primary CompletionJul 26, 2018
TodayJul 2, 2026
Enrollment to primary: 14.8 yearsPosted 18.8 years ago

Interventions

donor lymphocytesbiological

Given IV